Effect of mutational inactivation of tyrosine kinase activity on BCR/ABL-induced abnormalities in cell growth and adhesion in human hematopoietic progenitors

Cancer Research

Volumn 64, Issue 15, 2004, Pages 5322-5331

  Ramaraj, Pandurangan ^a,b   Singh, Harjeet ^a   Niu, Ning ^a   Chu, Su ^a   Holtz, Melissa ^a   Yee, Jung Kuan ^a   Bhatia, Ravi ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b CHARLES R DREW UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; BCR ABL PROTEIN; CD34 ANTIGEN; FIBRONECTIN; IMATINIB; PROLINE; PROTEIN KINASE INHIBITOR; RETROVIRUS VECTOR; STROMAL CELL DERIVED FACTOR 1ALPHA;

ACTIN BINDING DOMAIN; ARTICLE; BCR ABL GENE; CARBOXY TERMINAL SEQUENCE; CELL ADHESION; CELL CULTURE; CELL FUNCTION; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSFORMATION; CHEMOTAXIS; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INACTIVATION; FUSION GENE; GENE EXPRESSION; GENE MUTATION; GENE TRANSFER; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROLINE RICH DOMAIN; PROTEIN DOMAIN; PROTEIN MODIFICATION; SIGNAL TRANSDUCTION;

ACTINS; ANIMALS; ANTIGENS, CD34; ANTINEOPLASTIC AGENTS; CELL ADHESION; CELL DIVISION; CELL MOVEMENT; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; CHEMOKINES, CXC; CHEMOTAXIS; FIBRONECTINS; FUSION PROTEINS, BCR-ABL; GENE DELETION; GENETIC VECTORS; HEMATOPOIETIC STEM CELLS; HUMANS; MICE; MUTATION; PIPERAZINES; PROLINE; PROTEIN-TYROSINE KINASES; PYRIMIDINES;

EID: 3442885379     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-3656     Document Type: Article

References (60)

1. Rowley JD. A new consistent chromosome abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973;243:209-13.
2. DeKlein A, Van Kessel AG, Grosveld G, et al. A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukemia. Nature 1982;300:765-7.
3. Lugo T, Pendergast A, Muller A, Witte O. Tyrosine kinase activity and transformation potency of bcr/abl oncogene products. Science 1990;237:1079-82.
4. Daley GQ, Baltimore D. Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic leukemia-specific P210 bcr/abl protein. Proc Natl Acad Sci USA 1988;85:9312-6.
5. Pear WS, Miller JP, Xu L, et al. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood 1998;92:3780-92.
6. Li S, Ilaria RL, Million RP, Daley GQ, Van Etten RA. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. J Exp Med 1999;189:1399-412.
7. Sawyers CL. Chronic myeloid leukemia. N Engl J Med 1999;340:1330-40.
8. Bedi A, Griffin CA, Barber JP, et al. Growth factor-mediated terminal differentiation of chronic myeloid leukemia. Cancer Res 1994;54:5535-8.
9. Traycoff CM, Halstead B, Rice S, McMahel J, Srour EF, Cornetta K. Chronic myelogenous leukaemia CD34+ cells exit G0/G1 phases of cell cycle more rapidly than normal marrow CD34+ cells. Br J Haematol 1998;102:759-67.
10. Petzer AL, Eaves CJ, Barnett MJ, Eaves AC. Selective expansion of primitive normal hematopoietic cells in cytokine-supplemented cultures of purified cells from patients with chronic myeloid leukemia. Blood 1997;90:64-9.
11. Bhatia R, Munthe HA, Williams AD, Zhang F, Fortran SJ, Slovak ML. Increased sensitivity of chronic myelogenous leukemia primitive hematopoietic progenitors to growth factor induced cell division and maturation. Exp Hematol 2000;12:1401-12.
12. Bedi A, Zehnbauer BA, Barber JP, Sharkis SJ, Jones RJ. Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. Blood 1994;83:2038-44.
13. Maguer-Satta V, Burl S, Liu L, et al. BCR-ABL accelerates C2-ceramide-induced apoptosis. Oncogene 1998;16:237-48.
14. Amos TA, Lewis JL, Grand FH, Gooding RP, Goldman JM, Gordon MY. Apoptosis in chronic myeloid leukaemia: normal responses by progenitor cells to growth factor deprivation, X-irradiation and glucocorticoids. Br J Haematol 1995;91:387-93.
15. Ghaffari S, Daley GQ, Lodish HF. Growth factor independence and BCR/ABL transformation: promise and pitfalls of murine model systems and assays. Leukemia 1999;13:1200-6.
16. Eaves CJ, Gasman JD, Wolpe SD, Eaves AC. Unresponsiveness of primitive chronic myeloid leukemia cells to macrophage inflammatory protein 1 alpha, an inhibitor of primitive normal hematopoietic cells. Proc Natl Acad Sci USA 1993;90:12015-9.
17. Cashman JD, Eaves CJ, Sarris AH, Eaves AC. MCP-1, not MIP-1alpha, is the endogenous chemokine that cooperates with TGF-beta to inhibit the cycling of primitive normal but not leukemic (CML) progenitors in long-term human marrow cultures. Blood 1998;92:2338-44.
18. Gordon MY, Dowding CR, Riley GP, Goldman JM, Greaves MF. Altered adhesive interactions with marrow stroma of hematopoietic progenitor cells in chronic myelogenous leukaemia. Nature 1984;328:342-4.
19. Verfaillie CM, McCarthy JB, McGlave PB. Mechanisms underlying abnormal trafficking of malignant progenitors in chronic myelogenous leukemia: Decreased adhesion to stroma and fibronectin but increased adhesion to the basement membrane components laminin and collagen type IV. J Clin Investig 1992;90:1232-9.
20. Bhatia R, McCarthy JB, Verfaillie CM. Interferon-alpha restores normal beta 1 integrin-mediated inhibition of hematopoietic progenitor proliferation by the marrow microenvironment in chronic myelogenous leukemia. Blood 1996;87:3883-91.
21. Hurley RW, McCarthy JB, Verfaillie CM. Direct adhesion to bone marrow stroma via fibroneciin receptors inhibits hematopoietic progenitor proliferation. J Clin Investig 1995;96:511-9.
22. Jiang Y, Zhao RC, Verfaillie CM. Abnormal integrin-mediated regulation of chronic myelogenous leukemia CD34+ cell proliferation: BCR/ABL up-regulates the cyclin-dependent kinase inhibitor, p27Kip, which is relocated to the cell cytoplasm and incapable of regulating cdk2 activity. Proc Natl Acad Sci USA 2000;97:10538-43.
23. Peled A, Hardan I, Trakhtenbrot L, et al. Immature leukemic CD34+CXCR4+ cells from CML patients have lower integrin-dependent migration and adhesion in response to the chemokine SDF-1. Stem Cells 2002;20:259-66.
24. Salgia R, Li J-L, Ewaniuk DS, et al. BCR/ABL induces multiple abnormalities of cytoskeletal function. J Clin Invest 1997;100:46-57.
25. Salgia R, Quackenbush E, Lin J, et al. The BCR/ABL oncogene alters the chemotactic response to stromal-derived factor-1alpha. Blood 1999;94:4233-46.
26. Ptasznik A, Urbanowska E, Chinta S, et al. Crosstalk between BCR/ABL oncoprotein and CXCR4 signaling through a Src family kinase in human leukemia cells. J Exp Med 2002;196:667-78.
27. Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood 2000;96:3343-56.
28. Zhang X, Ren R. Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia. Blood 1998;92:3829-40.
29. Zhang X, Wong R, Hao SX, Pear WS, Ren R. The SH2 domain of bcr-Abl is not required to induce a murine myeloproliferative disease; however, SH2 signaling influences disease latency and phenotype. Blood 2001;97:277-87.
30. Roumiantsev S, de Aos IE, Varticovski L, Ilaria RL, Van Etten RA. The src homology 2 domain of Bcr/Abl is required for efficient induction of chronic myeloid leukemia-like disease in mice but not for lymphoid leukemogenesis or activation of phosphatidylinositol 3-kinase. Blood 2001;97:4-13.
31. He Y, Wertheim JA, Xu L, et al. The coiled-coil domain and Tyr177 of bcr are required to induce a murine chronic myelogenous leukemia-like disease by bcr/abl. Blood 2002;99:2957-68.
32. Wertheim JA, Perera SA, Hammer DA, Ren R, Boettiger D, Pear WS. Localization of BCR-ABL to F-actin regulates cell adhesion but does not attenuate CML development. Blood 2003;102:2220-8.
33. Druker B, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2:561-6.
34. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-7.
35. Kaur G, Gazit A, Levitzki A, Stowe E, Cooney DA, Sausville EA. Tyrphostin induced growth inhibition: correlation with effect on p210bcr-abl autokinase activity in K562 chronic myelogenous leukemia cells. Anti-Cancer Drugs 1994;5:213-22.
36. Druker B, Okuda K, Matulonis U, Salgia R, Roberts T, Griffin JD. Tyrosine phosphorylation of rasGAP and associated proteins in chronic myelogenous leukemia cell lines. Blood 1992;79:2215-20.
37. Skourides PA, Perera SA, Ren R. Polarized distribution of Bcr-Abl in migrating myeloid cells and co- localization of Bcr-Abl and its target proteins. Oncogene 1999;18:1165-76.
38. Heaney C, Kolibaba K, Bhat A, et al. Direct binding of CRKL to BCR-ABL is not required for BCR-ABL transformation. Blood 1997;89:297-306.
39. Pear WS, Nolan G, Scott M, Baltimore D. Production of high titer helper free retroviruses by transient transfection. Proc Natl Acad Sci USA 1993;90:8392-6.
40. Norris PS, Jepsen K, Haas M. High-liter MSCV-based retrovirus generated in the pCL acute virus packaging system confers sustained gene expression in vivo. J Virol Methods 1998;75:161-7.
41. Bhatia R, McGlave PB, Dewald GW, Blazar BR, Verfaillie CM. Abnormal function of the bone marrow microenvironment in chronic myelogenous leukemia: role of malignant stromal macrophages. Blood 1995;85:3636-45.
42. Bhatia R, Wayner EA, McGlave PB, Verfaillie CM. Interferon-alpha restores normal adhesion of chronic myelogenous leukemia hematopoietic progenitors to bone marrow stroma by correcting impaired beta 1 integrin receptor function. J Clin Jnvestig 1994;94:384-91.
43. Bhatia R, Munthe HA, Forman SJ. Abnormal growth factor modulation of β1-integrin mediated adhesion in chronic myelogenous leukemia hematopoietic progenitors. Br J Hematol 2001;115:845-53.
44. Wertheim JA, Forsythe K, Druker BJ, Hammer D, Boettiger D, Pear WS. BCR-ABL-induced adhesion defects are tyrosine kinase-independent. Blood 2002;99:4122-30.
45. Zhao RC, Jiang Y, Verfaillie CM. A model of human p210(bcr/ABL)-mediated chronic myelogenous leukemia by transduction of primary normal human CD34(+) cells with a BCR/ABL-containing retroviral vector. Blood 2001;97:2406-12.
46. Chalandon Y, Jiang X, Hazlewood G, et al. Modulation of p210(BCR-ABL) activity in transduced primary human hematopoietic cells controls lineage programming. Blood 2002;99:3197-204.
47. Cambier N, Chopra R, Strasser A, Metcalf D, Elefanty AG. BCR-ABL activates pathways mediating cytokine independence and protection against apoptosis in murine hematopoietic cells in a dose-dependent manner. Oncogene 1998;16:335-48.
48. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cylarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004.
49. Bhatia R, Munthe HA, Verfaillie CM. Tyrphosin AG 957, a tyrosine kinase inhibitor with anti-BCR/ABL tyrosine kinase activity restores β1 integrin mediated adhesion and inhibitory signaling in chronic myelogenous leukemia hematopoietic progenitors. Leukemia 1998;12:1708-17.
50. Bazzoni G, Carlesso N, Griffin JD, Hemler ME. Bcr/Abl expression stimulates integrin function in hematopoietic cell lines. J Clin Investig 1996;98:521-8.
51. McWhirter JR, Wang JYJ. An actin-binding function contributes to transformation by the BCR-ABL oncoprotein of Philadelphia chromosome-positive human leukemias. EMBO J 1993;12:1533-46.
52. Van Etten R, Jackson P, Baltimore D, Sanders M, Matsudaira P, Janmey P. The COOH terminus of c-Abl tyrosine kinase contains distinct F- and G-actin binding domains with bundling activity. J Cell Biol 1994;124:325-40.
53. McWhirter JR, Wang JY. Effect of Bcr sequences on the cellular function of the Bcr-Abl oncoprotein. Oncogene 1997;15:1625-34.
54. Heisterkamp N, Voncken JW, Senadheera D, et al. Reduced oncogenicity of p190 Bcr/Abl F-actin-binding domain mutants. Blood 2000;96:2226-32.
55. Dai Z, Kerzic P, Schroeder WG, McNiece IK. Deletion of the Src homology 3 domain and C-terminal proline-rich sequences in Bcr-Abl prevents Abl interactor 2 degradation and spontaneous cell migration and impairs leukemogenesis. J Biol Chem 2001;276:28954-60.
56. Oda T, Heaney C, Hagopian JR, Okuda K, Griffin JD, Druker BJ, Crk1 is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia. J Biol Chem 1994;269:22925-8.
57. Salgia R, Uemera N, Okuda K, et al. CRKL links p210BCR/ABL with paxillin in chronic myelogenous leukemia cells. J Biol Chem 1995;270:29145-50.
58. Stradal T, Courtney KD, Rottner K, Hahne P, Small JV, Pendergast AM. The Abl interactor proteins localize to sites of actin polymerization at the tips of lamellipodia and filopodia. Curr Biol 2001;11:891-5.
59. Hughes T, Kaeda J, Branford S, et al. Molecular responses to Imatinib (STI571) or Interferon + Ara-C as initial therapy for CML: Results in the IRIS study. Blood 2002;100:93A.
60. Bhatia R, Holtz M, Niu N, et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 2003;101:4701-7.